Report Detail
Global Gesagliflozin Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
- RnM4707744 |
- 09 June, 2026 |
- Global |
- 71 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Gesagliflozin market size was valued at US$ 30.87 million in 2025 and is forecast to a readjusted size of US$ 162 million by 2032 with a CAGR of 11.9% during review period.
In 2025, global Garsorasib production reached approximately 5000 units.Garsorasib Tablets (generic name: Garsorasib Tablets, trade name: Anfangning) is an independently developed oral small-molecule targeted antineoplastic drug in China for the treatment of KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC), belonging to irreversible KRAS G12C inhibitors. Its mechanism of action is to specifically bind and lock the inactive conformation of the mutant KRAS protein, block the abnormal activation of the downstream MAPK signaling pathway, thereby inhibiting tumor cell proliferation and inducing tumor cell apoptosis. This product is a 200 mg yellow oval film-coated tablet, approved for marketing in China in November 2024. It is mainly indicated for adult patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer who have received at least one prior systemic therapy. It serves as an important domestic innovative targeted drug in the field of precision therapy for lung cancer in China.
Garsorasib, as the second KRAS G12C inhibitor approved in China, occupies an important position in the underserved niche market of KRAS G12C-mutant non-small cell lung cancer, relying on the strong commercialization capability of Chia Tai Tianqing. With its inclusion in medical insurance and the successive launch of multiple domestic similar drugs (Fuzolasib, Golorasib, Jilemei), the market has shifted from an early "blue ocean" to a fiercely competitive stage. Its core advantages lie in domestic innovation, definite efficacy and favorable safety. In addition, price reduction through medical insurance negotiations has rapidly improved patient accessibility. In the future, market competition will focus on price, medical insurance coverage, clinical efficacy, combination therapy, indication expansion (such as colorectal cancer) and commercial channels. Relying on its first-mover advantage, medical insurance coverage and strong channels, Garsorasib is expected to maintain a stable share among similar domestic products, while facing challenges including price wars, medical insurance cost control and intensified competition from rival drugs.
This report is a detailed and comprehensive analysis for global Gesagliflozin market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Gesagliflozin market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Gesagliflozin market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Gesagliflozin market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Gesagliflozin market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Gesagliflozin
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Gesagliflozin market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include InventisBio, Shanghai Chia Tai Tianqing Pharmaceutical, WuXi AppTec Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Gesagliflozin market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
100mg
200mg
Market segment by Combination Therapy
Garsorasib and Immune Checkpoint Inhibitors
Garsorasib and FAK Inhibitors
Market segment by Production Technology
Innovator
Generic
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Application
KRAS G12C-Mutant Tumors
Non-Small Cell Lung Cancer (NSCLC)
Colorectal Cancer
Pancreatic Cancer
Others
Major players covered
InventisBio
Shanghai Chia Tai Tianqing Pharmaceutical
WuXi AppTec Pharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Gesagliflozin product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Gesagliflozin, with price, sales quantity, revenue, and global market share of Gesagliflozin from 2021 to 2026.
Chapter 3, the Gesagliflozin competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Gesagliflozin breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Gesagliflozin market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Gesagliflozin.
Chapter 14 and 15, to describe Gesagliflozin sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Gesagliflozin Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 100mg
- 1.3.3 200mg
- 1.4 Market Analysis by Combination Therapy
- 1.4.1 Overview: Global Gesagliflozin Consumption Value by Combination Therapy: 2021 Versus 2025 Versus 2032
- 1.4.2 Garsorasib and Immune Checkpoint Inhibitors
- 1.4.3 Garsorasib and FAK Inhibitors
- 1.5 Market Analysis by Production Technology
- 1.5.1 Overview: Global Gesagliflozin Consumption Value by Production Technology: 2021 Versus 2025 Versus 2032
- 1.5.2 Innovator
- 1.5.3 Generic
- 1.6 Market Analysis by Sales Channels
- 1.6.1 Overview: Global Gesagliflozin Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
- 1.6.2 Hospital
- 1.6.3 Retail
- 1.6.4 Online
- 1.7 Market Analysis by Application
- 1.7.1 Overview: Global Gesagliflozin Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.7.2 KRAS G12C-Mutant Tumors
- 1.7.3 Non-Small Cell Lung Cancer (NSCLC)
- 1.7.4 Colorectal Cancer
- 1.7.5 Pancreatic Cancer
- 1.7.6 Others
- 1.8 Global Gesagliflozin Market Size & Forecast
- 1.8.1 Global Gesagliflozin Consumption Value (2021 & 2025 & 2032)
- 1.8.2 Global Gesagliflozin Sales Quantity (2021-2032)
- 1.8.3 Global Gesagliflozin Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 InventisBio
- 2.1.1 InventisBio Details
- 2.1.2 InventisBio Major Business
- 2.1.3 InventisBio Gesagliflozin Product and Services
- 2.1.4 InventisBio Gesagliflozin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 InventisBio Recent Developments/Updates
- 2.2 Shanghai Chia Tai Tianqing Pharmaceutical
- 2.2.1 Shanghai Chia Tai Tianqing Pharmaceutical Details
- 2.2.2 Shanghai Chia Tai Tianqing Pharmaceutical Major Business
- 2.2.3 Shanghai Chia Tai Tianqing Pharmaceutical Gesagliflozin Product and Services
- 2.2.4 Shanghai Chia Tai Tianqing Pharmaceutical Gesagliflozin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Shanghai Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
- 2.3 WuXi AppTec Pharmaceutical
- 2.3.1 WuXi AppTec Pharmaceutical Details
- 2.3.2 WuXi AppTec Pharmaceutical Major Business
- 2.3.3 WuXi AppTec Pharmaceutical Gesagliflozin Product and Services
- 2.3.4 WuXi AppTec Pharmaceutical Gesagliflozin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 WuXi AppTec Pharmaceutical Recent Developments/Updates
3 Competitive Environment: Gesagliflozin by Manufacturer
- 3.1 Global Gesagliflozin Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Gesagliflozin Revenue by Manufacturer (2021-2026)
- 3.3 Global Gesagliflozin Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Gesagliflozin by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Gesagliflozin Manufacturer Market Share in 2025
- 3.4.3 Top 6 Gesagliflozin Manufacturer Market Share in 2025
- 3.5 Gesagliflozin Market: Overall Company Footprint Analysis
- 3.5.1 Gesagliflozin Market: Region Footprint
- 3.5.2 Gesagliflozin Market: Company Product Type Footprint
- 3.5.3 Gesagliflozin Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Gesagliflozin Market Size by Region
- 4.1.1 Global Gesagliflozin Sales Quantity by Region (2021-2032)
- 4.1.2 Global Gesagliflozin Consumption Value by Region (2021-2032)
- 4.1.3 Global Gesagliflozin Average Price by Region (2021-2032)
- 4.2 North America Gesagliflozin Consumption Value (2021-2032)
- 4.3 Europe Gesagliflozin Consumption Value (2021-2032)
- 4.4 Asia-Pacific Gesagliflozin Consumption Value (2021-2032)
- 4.5 South America Gesagliflozin Consumption Value (2021-2032)
- 4.6 Middle East & Africa Gesagliflozin Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Gesagliflozin Sales Quantity by Type (2021-2032)
- 5.2 Global Gesagliflozin Consumption Value by Type (2021-2032)
- 5.3 Global Gesagliflozin Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Gesagliflozin Sales Quantity by Application (2021-2032)
- 6.2 Global Gesagliflozin Consumption Value by Application (2021-2032)
- 6.3 Global Gesagliflozin Average Price by Application (2021-2032)
7 North America
- 7.1 North America Gesagliflozin Sales Quantity by Type (2021-2032)
- 7.2 North America Gesagliflozin Sales Quantity by Application (2021-2032)
- 7.3 North America Gesagliflozin Market Size by Country
- 7.3.1 North America Gesagliflozin Sales Quantity by Country (2021-2032)
- 7.3.2 North America Gesagliflozin Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Gesagliflozin Sales Quantity by Type (2021-2032)
- 8.2 Europe Gesagliflozin Sales Quantity by Application (2021-2032)
- 8.3 Europe Gesagliflozin Market Size by Country
- 8.3.1 Europe Gesagliflozin Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Gesagliflozin Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Gesagliflozin Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Gesagliflozin Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Gesagliflozin Market Size by Region
- 9.3.1 Asia-Pacific Gesagliflozin Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Gesagliflozin Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Gesagliflozin Sales Quantity by Type (2021-2032)
- 10.2 South America Gesagliflozin Sales Quantity by Application (2021-2032)
- 10.3 South America Gesagliflozin Market Size by Country
- 10.3.1 South America Gesagliflozin Sales Quantity by Country (2021-2032)
- 10.3.2 South America Gesagliflozin Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Gesagliflozin Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Gesagliflozin Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Gesagliflozin Market Size by Country
- 11.3.1 Middle East & Africa Gesagliflozin Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Gesagliflozin Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Gesagliflozin Market Drivers
- 12.2 Gesagliflozin Market Restraints
- 12.3 Gesagliflozin Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Gesagliflozin and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Gesagliflozin
- 13.3 Gesagliflozin Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Gesagliflozin Typical Distributors
- 14.3 Gesagliflozin Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Gesagliflozin. Industry analysis & Market Report on Gesagliflozin is a syndicated market report, published as Global Gesagliflozin Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Gesagliflozin market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
